David Brochu comes to Kedrion Biopharma with 32 years of industry experience, including over 17 years in manufacturing and development of biologicals. He has held various senior management positions in Development, Engineering and Operations in a number of pharmaceutical companies. At his most recent position at Talecris Plasma Resources, he was Vice President of Operations. While in this role, he led the startup operations and subsequent growth of Talecris’s Plasma Collection organization in the Western U.S.
“Dave’s appointment demonstrates our ongoing commitment to building a vibrant US operation, and I am very pleased to welcome him to Kedrion Biopharma.” said Paolo Marcucci, CEO. “His broad range of experiences and expertise in plasma therapeutics development and manufacturing will allow us to develop and sustain consistently high standards in our technical operations as we grow here in the United States.”
“Kedrion Biopharma has an exciting opportunity to assist in the growth and development in the fields of hematology, immunology and other areas of interest” said Brochu. “Biologic manufacturing and technical operations present many challenges but can be incredibly rewarding when you keep in mind the patients that we serve and the everyday obstacles they overcome.”
About Kedrion Biopharma
Kedrion Biopharma, Inc. United States is a fully owned subsidiary of Kedrion S.p.A, headquartered in Italy. Kedrion develops, manufactures and distributes human plasma derived products, which improve people’s quality of life. The company plays a major role worldwide providing critical therapies in 40 other countries. The company’s focus is on providing high quality products, relentless pursuit of research and development, and on the building of substantial industrial capacity to ensure continuous supply.
Additional information about Kedrion can be found at www.kedrionusa.com
